Inui Masashi, Ishida Hideki, Omoto Kazuya, Tanabe Tatsu, Hattori Motoshi, Hirano Hajime, Tanabe Kazunari
Department of Urology, Tokyo Women's Medical University.
Clin Transpl. 2011:127-43.
The first case of kidney transplantation at our institution was carried out in 1971, and this first renal transplant recipient is still living with a functioning kidney. From 1971 through the end of 2011, more than 3000 cases of kidney transplantation have been carried out at our institution. Since 1983, cyclosporine-based immunosuppression has been employed at our center. During this period, most of the patients were treated with cyclosporine- or tacrolimus-based immunosuppression. The latest outcomes of kidney transplantation seem to have significantly improved compared to earlier periods. Since 2000, 10 year-graft survival is more than 90% in living donor kidney transplantation and 82% in deceased donor kidney transplantation. To resolve the serious problem of donor organ shortage, expansion of the donor pool by various options such as transplantation using extended criteria donation, donation after cardiac death, ABO-incompatible (ABO-ILKT) donors, or crossmatch-positive donors, has been carried out at our institution over the last decade. We performed the first case of ABO-ILKT in 1989, and have performed more than 400 cases at our institution as of 2011. We will describe our experience of kidney transplantation, including ABO-ILKT, sensitized recipients, pathological analysis, pediatric renal transplantation, laparoscopic donor nephrectomy, and recurrent glomerulonephritis. The data shows good outcomes, however, we still have many issues to resolve to improve long-term renal transplant outcome and to reduce complications.
我院的首例肾移植手术于1971年实施,这位首例肾移植受者目前仍依靠移植肾存活。从1971年到2011年底,我院共开展了3000多例肾移植手术。自1983年起,我院中心开始采用以环孢素为基础的免疫抑制方案。在此期间,大多数患者接受了以环孢素或他克莫司为基础的免疫抑制治疗。与早期相比,肾移植的最新疗效似乎有了显著改善。自2000年以来,活体供肾移植的10年移植肾存活率超过90%,尸体供肾移植的10年移植肾存活率为82%。为了解决供体器官严重短缺的问题,在过去十年里,我院通过多种方式扩大供体库,如采用扩大标准供体捐献、心脏死亡后捐献、ABO血型不相容(ABO-ILKT)供体或交叉配型阳性供体进行移植。我院于1989年实施了首例ABO-ILKT手术,截至2011年已完成400多例。我们将介绍我院肾移植的经验,包括ABO-ILKT、致敏受者、病理分析、小儿肾移植、腹腔镜供肾切除术和复发性肾小球肾炎。数据显示疗效良好,然而,为了改善肾移植的长期疗效并减少并发症,我们仍有许多问题需要解决。